MEDICAL TECHNOLOGY SYSTEMS INC /DE/
NT 10-K, 1998-06-29
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Previous: PRIME BANCORP INC /PA, 11-K, 1998-06-29
Next: AMERICAN RICE INC, NT 10-K, 1998-06-29



 
<PAGE>
                                      (1)


                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549


                                   FORM 12b-25

                           NOTIFICATION OF LATE FILING

Check One):                                     Commission  File Number  0-16594

[X]Form 10-K and Form 10-KSB [ ]Form 11-K [ ]Form 20-F [ ] Form 10-Q and Form
10-QSB [ ] Form N-SAR
For Period Ended:  March 31, 1998 
                   --------------
[ ]Transition Report on Form 10-K
[ ]Transition Report on Form 20-F
[ ]Transition Report on Form 11-K
[ ]Transition Report on Form 10-Q
[ ]Transition Report on Form N-SAR
For the Transition Period Ended:  

     Read attached  instruction  sheet before  preparing  form.  Please print or
type.  

     Nothing in this form shall be  construed to imply that the  Commission  has
verified any information  contained  herein. 

     If the  notification  relates  to a portion of the  filing  checked  above,
identify the Item(s) to which the notification relates:


                                     PART I
                             REGISTRANT INFORMATION

Full Name of Registrant  Medical Technology Systems, Inc.
                         --------------------------------

Former Name if Applicable 
                         -----------------------------------------------------

Address of Principal  Executive Office (Street and Number) 12920 Automobile
                                                           ----------------
Boulevard
- ---------
City, State and Zip Code Clearwater, Florida 34622
                         -------------------------


                                     PART II
                             RULES 12b-25(b) and (c)

If the subject report could not be filed without  unreasonable effort or expense
and the  registrant  seeks  relief  pursuant to Rule  12b-25(b)  [?23,047],  the
following should be completed. (Check box if appropriate)

          [x]  (a) The reasons  described  in  reasonable  detail in Part III of
               this form could not be eliminated without  unreasonable effort or
               expense;

          [x]  (b) The subject annual  report,  semi-annual  report,  transition
               report on Form 10-K,  Form 20-F,  11-K or Form N-SAR,  or portion
               thereof  will be filed on or before the  fifteenth  calendar  day
               following  the  prescribed  due date;  or the  subject  quarterly
               report or transition report on Form 10-Q, or portion thereof will
               be filed on or  before  the  fifth  calendar  day  following  the
               prescribed due date;

          [ ] (c) The  accountant's  statement or other exhibit required by Rule
               12b-25(c) has been attached if applicable.



<PAGE>
                                       2


                                    PART III
                                    NARRATIVE

State below in  reasonable  detail the  reasons  why Form 10-K and Form  10-KSB,
20-F,  11-K, 10-Q and Form 10-QSB,  N-SAR,  or the transition  report or portion
thereof could not be filed within the prescribed period.

     The Company could not file its Form 10K for the fiscal year ended March 31,
     1998 within the  prescribed  time  period  without  unreasonable  effort or
     expense  due to the  complicated  nature  of the  transactions  related  to
     amended loan  agreements  with its bank, the  reorganization  of one of the
     Company's  subsidiaries  and  certain  logistical  problems  related to the
     filing.  The Company is  diligently  working to  complete  the Form 10K and
     expects to file it in its entirety on or before the fifteenth  calendar day
     following the prescribed due date. PART IV OTHER INFORMATION

1)   Name  and  telephone  number  of  person  to  contact  in  regard  to  this
     notification

     Michael P.  Conroy,  Chief  Financial  Officer  (813)576-6311
     ---------------------------------------------------------------------------
     (Name)                                       (Area Code)(Telephone Number)

2)   Have all other periodic  reports  required under section 13 or 15(d) of the
     Securities Exchange Act of 1934 or section 30 of the Investment Company Act
     of 1940 during the preceding 12 months or for such shorter  period that the
     registrant was required to file such report(s) been filed? If the answer is
     no,  identify  report(s).  [x] Yes [ ] No 

3)   Is it anticipated that any significant change in results of operations from
     the corresponding  period for the last fiscal year will be reflected by the
     earnings  statements  to be  included  in the  subject  report  or  portion
     thereof?  [x] Yes [ ] No 
          
          If  so,  attach  an  explanation  of  the  anticipated   change,  both
     narratively and quantitatively,  and, if appropriate, state the reasons why
     a reasonable estimate of the results cannot be made. See Attachment "A."


                        Medical Technology Systems, Inc.
- --------------------------------------------------------------------------------
                (Name of Registrant as specified in its charter)

has  caused  this  notification  to be signed on its  behalf by the  undersigned
thereunto duly authorized.

Date     June 29, 1998              By: /s/ Michael P. Conroy
- ----------------------              -------------------------------------------
                                      Michael P.Conroy, Chief Financial Officer

INSTRUCTION: The form may be signed by an executive officer of the registrant or
by any other duly  authorized  representative.  The name and title of the person
signing  the form  shall  be typed or  printed  beneath  the  signature.  If the
statement is signed on behalf of the registrant by an authorized  representative
(other than an executive officer), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.

                                    ATTENTION

     Intentional  misstatements or omissions of fact constitute Federal criminal
violations (See 18 U.S.C. 1001).

                              GENERAL INSTRUCTIONS

1.       This  form is  required  by Rule  12b-25  (17 CFR 240,  12b-25)  of the
         General  Rules and  Regulations  under the  Securities  Exchange Act of
         1934.
2.       One  signed  original  and  four  conformed  copies  of this  form  and
         amendments  thereto must be completed and filed with the Securities and
         Exchange  Commission,  Washington,  D.C. 20549, in accordance with Rule
         0-3 of the General Rules and Regulations under the Act. The information
         contained in or filed with the Form will be made a matter of the public
         record in the Commission files.
3.       A manually  signed  copy of the form and  amendments  thereto  shall be
         filed  with each  national  securities  exchange  on which any class of
         securities of the registrant is registered.
4.       Amendments to the  notifications  must also be filed on Form 12b-25 but
         need not restate  information  that has been correctly  furnished.  The
         form shall be clearly identified as an amended notification.
5.       Electronic  Filers.  This form shall not be used by  electronic  filers
         unable to timely file a report solely due to  electronic  difficulties.
         Filers unable to submit a report within the time period  prescribed due
         to difficulties in electronic filing should comply with either Rule 201
         or Rule 202 of Regulation S-T or apply for an adjustment in filing date
         pursuant to Rule 13(b) of Regulation S-T.



<PAGE>
                                       1



                                  Attachment A

         Medical  Technology  Systems,  Inc.  (the  "Company")  expects that its
earnings for the year ended March 31, 1998 ("Fiscal 1998") will be significantly
lower than its earnings for the year ended March 31, 1997 ("Fiscal 1997").  The
Company reported a net profit of approximately $13.0 million for fiscal 1997 and
expects to report a net loss of approximately $1.0 million for fiscal 1998.

         The Company  attributes the large decrease in earnings to the fact that
the net income for fiscal 1997 included  extraordinary  gains recognized on debt
forgiveness of $13.6 million  associated with the  reorganization  of several of
its subsidiaries.  In addition, the Company recognized a gain of $2.2 million on
the disposal of one of its  discontinued  operations  during  fiscal  1997.  The
Company did not have  extraordinary  gains or gains on disposal of  discontinued
operations during fiscal 1998. Therefore, although the Company expects to report
a revenue  increase in Fiscal 1998 compared to the previous  year, new income is
expected to decrease by approximately $14.0 million.



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission